Results 1 to 10 of about 760 (154)
Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. [PDF]
PharmacotherapyAbstract Background Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii ...
Kufel WD +8 more
europepmc +5 more sources
Canadian Journal of Infectious Diseases and Medical MicrobiologyPurpose: To evaluate the pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial activity, efficacy, safety, and the regulatory status of sulbactam–durlobactam. Summary: Sulbactam–durlobactam is a recently approved antimicrobial combination of two β‐lactamase inhibitors for the treatment of hospital‐acquired bacterial pneumonia (HABP) and ...
Hanine Mansour, Wissam Kabbara
exaly +2 more sources
ChemMedChem, Volume 18, Issue 9, May 2, 2023., 2023 Ruthenium(II)‐catalyzed cycloaddition (RuAAC) is a powerful way to access 1,5‐disubsituted and 1,4,5‐trisubstituted triazole DBOs with complete control of regioselectivity. The biological activity of di‐ and tri‐substituted DBOs gave promising activity against a hyperpermeable strain of Escherichia coli producing KPC‐2, and molecular docking showed ...
Flavie Bouchet +7 more
wiley +1 more source
Case Reports in Infectious Diseases, Volume 2023, Issue 1, 2023., 2023 Carbapenem‐resistant Acinetobacter baumannii infection is a critically prioritized pathogen by the World Health Organization and a cause for growing concern due to increased mortality among hospitalised patients. Phrenic nerve palsy is a rare complication of herpes zoster infection of the C3, C4, and C5 nerve roots.
Yvonne Ayerki Nartey +5 more
wiley +1 more source
Superbugs or multidrug resistant microbes: A new threat to the society
, 2023 Health Science Reports, Volume 6, Issue 8, August 2023.
Sakshi Painuli +3 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley +1 more source
ChemMedChem, Volume 21, Issue 9, 14 May 2026.Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez +4 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov +7 more
wiley +1 more source
International Journal of Microbiology, Volume 2026, Issue 1, 2026.β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi +9 more
wiley +1 more source